Gland Pharma
Gland Pharma Limited, commonly referred to as Gland Pharma, is a prominent player in the pharmaceutical industry, headquartered in Hyderabad, India. Established in 1978, the company has made significant strides in the development and manufacturing of high-quality injectable pharmaceuticals, particularly in the areas of oncology, anaesthesia, and critical care. With a strong presence in both domestic and international markets, Gland Pharma has earned a reputation for its robust product portfolio, which includes a range of generic injectables and complex formulations. The company is recognised for its commitment to quality and innovation, having achieved several key milestones, including successful partnerships with global healthcare providers. Gland Pharma's dedication to excellence positions it as a leader in the injectable segment, contributing to improved patient outcomes worldwide.
DitchCarbon Score
How does Gland Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Gland Pharma's score of 21 is lower than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Gland Pharma's reported carbon emissions
In 2024, Gland Pharma reported total carbon emissions of approximately 15,736,000 kg CO2e for Scope 1 and about 81,154,000 kg CO2e for Scope 2, totalling around 96,890,000 kg CO2e. This data reflects their operations in India and globally, with a revenue of about USD 679,886,845. Comparatively, in 2023, the company recorded Scope 1 emissions of approximately 11,929,600 kg CO2e and Scope 2 emissions of about 80,669,600 kg CO2e, resulting in total emissions of around 92,599,200 kg CO2e. This indicates a slight increase in emissions from 2023 to 2024. Gland Pharma has not disclosed any Scope 3 emissions data, which typically includes indirect emissions from the supply chain and product use. Furthermore, there are no specific reduction targets or climate pledges outlined in their current commitments, indicating a potential area for future focus. The emissions data is cascaded from Gland Pharma Limited, reflecting their status as a current subsidiary. The company has not reported any initiatives under the Science Based Targets initiative (SBTi) or other climate-related frameworks, suggesting that while they are tracking emissions, they may not yet have formalised reduction strategies in place.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 12,579,300 | 00,000,000 | 00,000,000 |
| Scope 2 | 78,475,200 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Gland Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
